Increase of the duration of the anticonvulsive activity of a novel NMDA receptor antagonist using poly(butylcyanoacrylate) nanoparticles as a parenteral controlled release system

European Journal of Pharmaceutics and Biopharmaceutics

Volumn 49, Issue 2, 2000, Pages 103-109

  Friese, Andreas ^a   Seiller, Erhard ^a   Quack, Günter ^a   Lorenz, Bianka ^a   Kreuter, Jörg ^b  

^a Merz+Co ^*  (Germany)

^b GOETHE UNIVERSITY   (Germany)

Author keywords

Choroid plexus; Controlled release; Drug targeting; Glycine(B) site; Nanoparticles; NMDA receptor antagonist MRZ 2 576; Polysorbate 80; Probenecid

Indexed keywords

ENBUCRILATE; N METHYL DEXTRO ASPARTIC ACID; NANOPARTICLE; PROBENECID; QUINOLINE DERIVATIVE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BLOOD BRAIN BARRIER; CENTRAL NERVOUS SYSTEM; CHOROID PLEXUS; CONTROLLED DRUG RELEASE; CONVULSION; DRUG ACTIVITY; DRUG DELIVERY SYSTEM; DRUG DETERMINATION; DRUG ELIMINATION; FEMALE; MOUSE; NONHUMAN; PARTICLE SIZE;

ANIMALS; ANTICONVULSANTS; DRUG DELIVERY SYSTEMS; ENBUCRILATE; EXCITATORY AMINO ACID ANTAGONISTS; FEMALE; MICE; PHTHALAZINES; POLYSORBATES; PROBENECID; RECEPTORS, N-METHYL-D-ASPARTATE; TIME FACTORS;

EID: 0033993565     PISSN: 09396411     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0939-6411(99)00073-9     Document Type: Article

References (21)

1. Danysz W., Parsons C.G., Bresink I., Quack G. Glutamate in CNS disorders. DN&P. 8:(5):1995;261-277.
2. Parsons C.G., Danysz W., Quack G., Hartmann S., Lorenz B., Wollenburg C., Baran L., Przegalinski E., Kostowski W., Krzascik P., Chizh B., Headley P.M. Novel systemically-active antagonists of the glycine site of the NMDA receptor: electro-physiological, biochemical and behavioral characterization. J. Pharmacol. Exp. Ther. 283:1997;264-275.
3. Leeson P.D., Iversen L.L. The glycine site on the NMDA receptor: structure-activity relationship and therapeutic potential. J. Med. Chem. 24:(37):1994;4053-4067.
4. Taylor C.P., Vartanian M.G. Probenecid pretreatment enhances anticonvulsant action of NBQX in mice. Eur. J. Pharmacol. 213:1992;151-153.
5. Adkison K.D., Artru A.A., Powers K.M., Shen D.D. Contribution of probenecid sensitive anion transport processes at the brain capillary endothelium and choroid plexus to the efficient efflux of valproic acid from the central nervous system. J. Pharmacol. Exp. Ther. 268:(2):1994;797-805.
6. M.B. Hesselink, H. Smolders, W. Danysz, B. Lorenz, B. Eilbacher, A.G. de Boer, D.D. Breimer, Pharmacokinetik characterization of two distinct classes of NMDA receptor antagonists using brain microdialysis, Abstr. Neurosci. Meeting New Orleans 367.18, 1997.
7. Alyautdin R., Petrov V.E., Langer K., Berthold A., Kharkevich D.A., Kreuter J. Delivery of loperamide across the blood-brain barrier with polysorbate 80-coated polybutyl-cyanoacrylate nanoparticles. Pharm. Res. 14:1997;325-328.
8. Kreuter J. Evaluation of nanoparticles as drug-delivery-systems: I. Preparation methods. Pharm. Acta Helv. 58:1983;196-209.
9. Langer K., Seegmüller E., Zimmer A., Kreuter J. Characterisation of polybutyl-cyanoacrylate nanoparticles: I. Quantification of PBCA polymer and dextrans. Int. J. Pharm. 110:1994;21-27.
10. Parsons C.G., Quack G., Bresink I., Baran L., Przegalinski E., Kostowski W., Krzascik P., Hartmann S., Danysz W. Comparison of the potency, kinetics and voltage-dependency of a series of uncompetitive NMDA receptor antagonists in vitro with anti-convulsive and motor impairment activity in vivo. Neuropharmacology. 34:1995;1239-1258.
11. Swinyard E.A., Brown W.C., Goodman L.S. Comparative assays of antiepileptic drugs in mice and rats. J. Pharmacol. Exp. Ther. 106:1952;319-330.
12. Alyautdin R., Gothier D., Petrov V., Kharkevich D., Kreuter J. Analgesic activity of the hexapeptide dalargin adsorbed on the surface of polysorbate 80-coated poly(butylcyanoacrylate) nanoparticles. Eur. J. Pharm. Biopharm. 41:(1):1995;44-48.
13. Alyautdin R.N., Tezikov E.B., Ramge P., Kharkevich D.A., Begley D.J., Kreuter J. Significant entry of tubocurarine into the brain of rats by adsorption to polysorbate 80-coated polybutylcyanoacrylate nanoparticles: an in situ brain perfusion study. J. Microencaps. 1:(15):1998;67-74.
14. 14C-methacrylate) nanoparticle radioactivity after injection in rats and mice. J. Pharm. Sci. 68:1979;1443-1449.
15. Grislain L., Couvreur P., Lenaerts V., Roland M., Deprez-Decampeneere D., Speiser P. Pharmacokinetics and distribution of a biodegradable drug-carrier. Int. J. Pharm. 15:1983;333-345.
16. Tröster S.D., Müller U., Kreuter J. Modification of the body distribution of poly(methylmethacrylate) nanoparticles in rats by coating with surfactants. Int. J. Pharm. 61:1990;85-100.
17. Müller R.H., Lherm C., Herbort J., Blunk T., Couvreur P. Alkylcyanoacrylate drug carriers: I. Physicochemical characterization of nanoparticles with different alkyl chain length. Int. J. Pharm. 84:1992;1-11.
18. Stein M., Hamacher E. Degradation of polybutyl 2-cyanoacrylate microparticles. Int. J. Pharm. 80:1992;R11-R13.
19. Scherer D., Robinson J.R., Kreuter J. Influence of enzymes on the stability of polybutylcyanoacrylate nanoparticles. Int. J. Pharm. 101:1994;165-168.
20. Goodman Gilman A., Goodman L.S. The Pharmacological Basis of Therapeutics. 1985;Macmillan, New York.
21. Zamboni W.C., Houghton P.J., Johnson R.K., Hulstein J.L., Crom W.R., Cheshire P.J., Hanna S.K., Richmond L.B., Luo X., Stewart C.F. Probenecid alters topotecan systemic and renal disposition by inhibiting renal tubular secretion. J. Pharmacol. Exp. Ther. 284:1998;89-94.